Exploratory observational study on prediction based on PK / PD / PGx of efficacy and safety of palbociclib for patients with inoperable or recurrent breast cancer

Exploratory observational study on prediction based on PK / PD / PGx of efficacy and safety of palbociclib for patients with inoperable or recurrent breast cancer - NCCH1701

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029954

Enrollment

200

Registered

2017-11-14

Start date

2017-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 20 years or older who are diagnosed as inoperable or recurrent breast cancer and scheduled to receive palbociclib. 2. Patients who have provided a written informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: No setting

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Progression-free survival Overall survival Incidence of adverse events	—

Countries

Japan

Contacts

Public ContactEmi Noguchi

National Cancer Center Hospital Department of Breast and Medical Oncology

enoguchi@ncc.go.jp03-3542-2511

Outcome results